InflaRx (IFRX) Cash from Investing Activities Growth (3y) (2019 - 2026)
InflaRx (IFRX) Cash from Investing Activities Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -44.69% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -39.73% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -246.81% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -177.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.84% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -53.57% |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.96% |
| Dec 31, 2025 | 70.71% |
| Sep 30, 2025 | -15.46% |
| Jun 30, 2025 | -23.79% |
| Mar 31, 2025 | -14.51% |
| Dec 31, 2024 | 27.12% |
| Sep 30, 2024 | 18.98% |
| Jun 30, 2024 | 100.02% |
| Mar 31, 2024 | 192.87% |
| Dec 31, 2023 | 32.47% |
| Sep 30, 2023 | -8.41% |
| Jun 30, 2023 | -44.95% |
| Mar 31, 2023 | -8.69% |
| Dec 31, 2022 | -58.43% |
| Sep 30, 2022 | 30.58% |
| Jun 30, 2022 | -40.28% |
| Mar 31, 2022 | 367.03% |
| Dec 31, 2021 | -97.13% |
| Sep 30, 2021 | 28.08% |
| Jun 30, 2021 | 52.48% |